Clomiphene


Clomiphene citrate (USA trade name Clomid) is a selective estrogen receptor modulator (SERM) that increases production of the body's gonadotropins via disruption of the natural negative feedback system in the hypothalamus. Clomiphene consists of two bioactive isomers, zuclomifene and enclomiphene. Zuclomifene is responsible for the primary effects of clomiphene, which consists of binding to estrogen receptors for long periods of time. Because the receptors cease recycling (and cannot be reused) for the duration, the hypothalamic estrogen number decreases, meaning the body's feedback system tells it that there is low estrogen. Estrogen modulation is the body's primary method of initiating and controlling negative hypothalamic feedback; with perceived low estrogen, GnRH pulsatility is increased and the pituitary releases more luteinizing hormone (LH) and follicle stimulating hormone (FSH).[1]



Clomiphene is primarily used to treat female fertility issues via its ability to increase the body's gonadotropin release.[1] It is also useful for reasons related to the same mechanisms, as well as novel and newly discovered mechanisms, in treating various forms of male infertility.[1]



Schellen writes and highlights well the diverse uses and progressive versatility shown with clomiphene as a potential treatment for an array of issues:



After the discovery that Clomiphene-citrate (Clomid) increased the secretion of gonadotropins, it was first used to induce ovulation and later on it was also used in males in certain cases of infertility. The effects of Clomid on the hypothalamic-pituitary level made it also possible to use it for a dynamic evaluation of the hypothalamic-pituitary gonadal axis in both females and males. [2]



Clomiphene is often used by bodybuilders who self-administer anabolic-androgenic steroids (AAS) to control undesirable estrogenic side-effects such as gynecomastia, acne, and mood-swings, similar to the way drug tamoxifen and the aromatase inhibitors letrozole, exemestane, and anastrozole are used. Users of AAS also frequently use clomid to exploit its gonadotropin-stimulating effect, in order to increase testosterone levels from a suppressed baseline after a "cycle" of steroids via release of gonadotropin releasing-hormone, follicle stimulating hormone, and luteinizing hormone.



In some cases clomiphene may be preferable over other options such as testosterone therapy for hypogonadism because, as the researches quoted below note, testosterone administration actually causes infertility in many cases; further, as many cases of hypogonadism may be steroid-abuse-induced, testosterone would be ruled out in those cases:



Hypogonadism has a number of important clinical consequences related to androgen deficiency and impaired spermatogenesis. The cause of this condition is multifactorial and can result from hypothalamic, pituitary or gonadal dysfunction as well as factors that affect hormonal signaling along the hypothalamic-pituitary-gonadal axis. While testosterone replacement is the most common treatment, it can paradoxically lead to infertility, and may be a less physiologic therapy for patients with secondary hypogonadism due to pituitary dysfunction. Clomiphene citrate, and its derivatives, may allow for restoration of gonadal function by restoring physiologic pituitary function in a subset of patients with hypogonadism.[3]



Tan and Vasudevan document a case study in which clomiphene successfully treated (by standards of testosterone levels, LH pulsatility, and restoration of pituitary-gonadal axis and feedback system) premature andropause induced by long-term steroid abuse:



Clomiphene citrate is used typically in helping to restore fertility in females. This represents the first case report of the successful use of clomiphene to restore T levels and the pituitary-gonadal axis in a male patient. The axis was previously shut off with multiple anabolic steroid abuse.[4]



Taylor and Levine find clomiphene citrate suitable for long-term use in place of testosterone gel replacement therapy for treating sexual dysfunction and the set of symptoms generally associated with hypogonadism or andropause:



CC represents a treatment option for men with hypogonadism, demonstrating biochemical and clinical efficacy with few side effects and lower cost as compared with TGRT.[5]



Kanayama et al recommend clomiphene as part of a comprehensive treatment program for AAS abusers:



...AAS suppress the male hypothalamic-pituitary-gonadal axis via their androgenic effects, potentially causing hypogonadism during AAS withdrawal. Men experiencing prolonged dysphoric effects or frank major depression from hypogonadism may desire to resume AAS, thus contributing to AAS dependence. AAS-induced hypogonadism may require treatment with human chorionic gonadotropin or clomiphene to reactivate neuroendocrine function, and may necessitate antidepressant treatments in cases of depression inadequately responsive to endocrine therapies alone.[6]



Citations:

[1]Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.

[2]Schellen TM. Clomiphene treatment in male infertility. Int J Fertil. 1982;27(3):136-45.

[3]Kaminetsky J, Hemani ML. Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency. Expert Opin Investig Drugs. 2009 Dec;18(12):1947-55.

[4]Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril. 2003 Jan;79(1):203-5.

[5]Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010 Jan;7(1 Pt 1):269-76.

[6]Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications. Drug Alcohol Depend. 2010 Jun 1;109(1-3):6-13.



More Peptide Info...




CJC-1295 DAC 5mg

CJC-1295 DAC 5mg





CJC-1295 DAC has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC - 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.

is a long acting Growth Hormone Releasing Hormone, which causes the anterior pituitary to release more growth hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).

CJC-1295 DAC vs. CJC-1295 No DAC

CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse of Human Growth Hormone.

ConjuChem and The Development of CJC-1295 DAC

CJC-1295 DAC is a tetrasubstituted peptide analogue of Growth Hormone Releasing Hormones with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. A Canadian biotechnology company called ConjuChem had invented CJC-1295. Clinical Research on CJC-1295 first began during the mid-2000s. The goal of the peptide, acting to raise hgh like Ipamorelin, was to treat visceral fat deposits in obese AIDS patients because it is presumed that increased levels of exogenous hgH increase fat loss, or lipolysis. In one study, results showed that the measured GH release in rats over a two hour period showed that CJC-1295 released twice as much GH as CJC-1293 DAC. This result makes it preferable for immediate effectiveness as a result of the longer peak. With the use of a Growth Hormone Releasing Peptide (GHRP), such as Growth Hormone Releasing Hexapeptide (GHRP-6) in conjuction with CJC-1295 DAC, a study has shown that the GHRP’s create a Growth Hormone pulse which helps the CJC-1295 work effectively. Clinical research's involving CJC-1295 have shown that it had been successful for most research subjects..


More Peptide Info...




SARMs S4



SARMs, Selective Androgen Receptor Modulators, are a relatively new class of research chemicals that have selective androgenic activity in a given area of the body.[1]  The specific activity is determined by which androgen receptors are activated and in what tissue.[1]  The clinical capability of SARMs is expected to be more broad and diverse than anabolic/androgenic steroids like testosterone, which are almost never a first choice for treatment.[1]  Testosterone and its ilk are considered unsuitable because their androgenic activity is systemic, meaning that undesirable side effects such as virilization in women, left ventricular hypertrophy in patients receiving doses exceeding a certain level, and various other effects that are difficult to prevent are commonplace


In addition to the specific targeted nature of the first-generation SARMs, they offer a major advantage in practical applied treatment over the androgens: they can be dosed orally without liver toxicity, which means that applied treatments require less training of subjects and in the future, use of the research chemicals may be possible for a larger group where injection or oral toxicity of anabolic steroids previously prevented indication by practitioners.[1]


Ke and Wang speculate that in elderly men with osteoporosis, or at risk of osteoporosis, could benefit from SARM therapy that (unlike testosterone and its derivatives) does not have any activity on the testes or prostate.[2]




While future SARMs may be developed with zero androgenic effect in target tissue at all, which would provide benefits such as (for example) anabolism of bone or muscle tissue with zero side effects, current SARMs all have some degree of androgenic effect in tissue, though still less than testosterone.  The anabolic/androgenic ratio of SARMs currently available is between 3:1 and 10:1, whereas testosterone is 1:1.[3]



S-4 is an experimental or investigation-stage proprietary SARM research chemical developed by GTx Inc for treatment of benign prostatic hypertrophy, muscle wasting, and osteoporosis.[4]  S-4 is considered a partial agonist of the androgen receptors in target tissue.[3] S-4 has less pronounced  anabolic and androgenic compared to other SARMs. In trials treating BPH induced in animal models, S-4 reduced prostate weight as effectively as finasteride and without producing any reduction in muscle mass or other side effects common with androgen receptor binding compounds.[5] Gao et al suggest that by binding to androgen receptors, S-4 prevents DHT from binding and activating, but bypasses the expected anti-androgenic effects that would occur from occupying androgen receptors due to the fact that S-4 itself is a partial agonist of androgen receptors.[6]  S-4 has also been shown to prevent bone loss, reduce body fat, and improve muscle strength and body composition in orchidectomized and ovariectomized rats.[7,8]


1] Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD.  Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. Journal of Medicinal Chemistry 52 (12): 3597–617. 2009.
[2] Ke HZ, Wang XN, O'Malley J, Lefker B, Thompson DD. Selective androgen receptor modulators--prospects for emerging therapy in osteoporosis? J Musculoskelet Neuronal Interact 5 (4): 355. 2005.
[3]Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT. Pharmacodynamics of selective androgen receptor modulators. Journal of Pharmacology and Experimental Therapeutics. 2003 Mar;304(3):1334-40.
[4]Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. 26 (11): 1563–9. 2003.
[5] Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology. 2004 Dec;145(12):5420-8.
[6] Gao W, Kim J, Dalton JT. Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharmaceutical Research. 2006 Aug;23(8):1641-58.
[7] Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007 Feb;24(2):328-35.
[8] Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, Dalton JT. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats.  Endocrinology. 2005 Nov;146(11):4887-97.





More Peptide Info...